直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Article

Favorable Capital Gains Taxation Rates Apply to Payments for Transfer of All Substantial Rights in Patents

April 4, 2017

LES Insights

By John C. Paul; D. Brian Kacedon; Jonathan J. Fagan

Authored by Jonathan J. Fagan, D. Brian Kacedon, and John C. Paul

Abstract

The portion of a termination payment attributable to a transfer of all substantial rights in a patent may be treated as long-term capital gain and taxed at more favorable rates than ordinary income. Such favorable tax treatment can be enjoyed by members of a partnership that has received payment for transferring those patent rights.


A patent holder may treat payments from the sale or exchange of a patent as long-term capital gain under IRC 1235, which taxes such gains at a lower rate than ordinary income. In January 2017 the IRS considered whether the individual partners in a partnership could count a portion of a termination payment under an agreement between a partnership and a company as transferring all substantial rights in a patent as long-term capital gain under § 1235.

Background

A partnership of four individuals transferred certain "Rights in Product" to a company that agreed to pay the partnership based on sales of the Product. The partnership represented that this agreement transferred all substantial rights to a patent within the meaning of § 1235. For two years, the partners reported payments received under the agreement as long-term capital gains under § 1235. The partnership and the company later entered into a second agreement that terminated the first agreement and required the company to make a termination payment to the partnership. This second agreement allocated a portion of the termination payment as a final payment satisfying the company’s payment obligations under the first agreement. The partners asked the IRS for a Private Letter Ruling whether they could treat this portion of the termination payment as long-term capital gain.

The Private Letter Ruling

Section 1235 of the Internal Review Code applies only to a "holder"—that is, an individual whose efforts created the property consisting of all substantial rights in a patent. The IRS Ruling explained that although a partnership cannot be a holder, each member of a partnership who is an individual may qualify as a holder as to their share of a patent owned by the partnership. For the termination payment to the partnership, the IRS assumed that 1) the first agreement constituted a transfer of all substantial rights in a patent; and 2) each individual partner qualified as a "holder." Accordingly, the IRS concluded that the portion of the termination payment that was allocated as a final payment for the termination of the company’s payment obligations under the first agreement qualifies as long-term capital gain under § 1235 as to each individual partner’s distributive share of income attributable to the transfer.

Strategy and Conclusion

Although IRS Private Letter Rulings do not bind the IRS and parties may not cite them as precedent, this decision illustrates the importance of properly identifying certain portions of a payment to qualify for preferential capital gain treatment under § 1235.

Further Information

The Private Letter Ruling can be found here.

Related Practices

Prosecution and Portfolio Management

Related Professionals

John C. Paul
Partner
Washington, DC
+1 202 408 4109
Email
D. Brian Kacedon
Partner
Washington, DC
+1 202 408 4301
Email
Jonathan J. Fagan
Associate
Washington, DC
+1 202 408 4119
Email

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm’s clients.

Related Insights

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Conference

Atlantic Basin Conference on Chemistry 2026

December 6-9, 2026

Rio de Janeiro

Panel Discussion

2026 Advanced Patent Law Institute

December 3-4, 2026

Stanford

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

IPBC Asia 2026

November 17-19, 2026

Tokyo

Conference

NAPABA Convention 2026

November 12-14, 2026

Los Angeles

Conference

Broad's 3rd Annual Biotech IP Summit

November 10, 2026

Cambridge

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP